
Sign up to save your podcasts
Or


A new kind of disruptor is threatening the bottom line of the world's biggest food corporations: GLP-1 drugs like Ozempic. In this fascinating episode of The Dark Side of Dining, host Kenny Mears welcomes back Sylvain Charlebois, The Food Professor, to analyze how these weight-loss drugs are fundamentally changing the way people eat—and what that means for fast food and snack giants.
Charlebois calls GLP-1s the "quiet disruptor," revealing that even the "golden standard"—McDonald's—has publicly acknowledged the drugs as a problem impacting customer traffic.
Learn what these "miracle" drugs do: originally designed for type 2 diabetes, GLP-1s dramatically suppress the craving for sugar and salt—the very ingredients that fuel impulse buying and are the basis of the modern processed food business model.
Professor Charlebois reveals the predicted shift in consumer behavior:
The food industry is racing to adapt, much like they did with the rise of plant-based foods. Charlebois predicts a "democratization of menus":
This medical breakthrough is causing a "massive shift" in the industry, even contributing to the bankruptcy of traditional diet companies like Weight Watchers. Is the future of food about medical intervention rather than nutrition advocacy?
Tune in to discover how a simple pill is challenging the core mechanisms of the global food market and forcing a dramatic, market-driven overhaul of what we eat.
Check out The Food Professor!:
X: https://x.com/foodprofessor?lang=en
Podcast: https://the-food-professor.simplecast.com/
Follow The Dark Side of Dining:
Instagram: https://www.instagram.com/thedarksideofdining?igsh=cGkwdXp1MWRuN2tp
Facebook: https://www.facebook.com/share/1G88ZywYK5/
By Food For Thought AudioA new kind of disruptor is threatening the bottom line of the world's biggest food corporations: GLP-1 drugs like Ozempic. In this fascinating episode of The Dark Side of Dining, host Kenny Mears welcomes back Sylvain Charlebois, The Food Professor, to analyze how these weight-loss drugs are fundamentally changing the way people eat—and what that means for fast food and snack giants.
Charlebois calls GLP-1s the "quiet disruptor," revealing that even the "golden standard"—McDonald's—has publicly acknowledged the drugs as a problem impacting customer traffic.
Learn what these "miracle" drugs do: originally designed for type 2 diabetes, GLP-1s dramatically suppress the craving for sugar and salt—the very ingredients that fuel impulse buying and are the basis of the modern processed food business model.
Professor Charlebois reveals the predicted shift in consumer behavior:
The food industry is racing to adapt, much like they did with the rise of plant-based foods. Charlebois predicts a "democratization of menus":
This medical breakthrough is causing a "massive shift" in the industry, even contributing to the bankruptcy of traditional diet companies like Weight Watchers. Is the future of food about medical intervention rather than nutrition advocacy?
Tune in to discover how a simple pill is challenging the core mechanisms of the global food market and forcing a dramatic, market-driven overhaul of what we eat.
Check out The Food Professor!:
X: https://x.com/foodprofessor?lang=en
Podcast: https://the-food-professor.simplecast.com/
Follow The Dark Side of Dining:
Instagram: https://www.instagram.com/thedarksideofdining?igsh=cGkwdXp1MWRuN2tp
Facebook: https://www.facebook.com/share/1G88ZywYK5/